energy stocks newswire

Friday, January 7, 2011

Trading Alert: OTCBB Stocks to Watch; (OTCBB: AMOK), (OTCBB: ESPH), (OTCBB: ACTC), (OTCBB: GNBT)

Point Roberts, WA –January 7, 2011 ( Newswire) -, leader
in sector research for investors, including OTCBB stocks, reports on recent news and trading for
January 7th OTC Volume Leaders. Sectors Include Biotech, Energy and Mining.

Volume Leaders include Amarok Resources, Inc. (OTCBB: AMOK), Advanced Cell Technology
Technologies, Inc. (ESPH.OB)

Energy Stocks trading at close January 7, 2010

Amarok Resources, Inc. (OTCBB: AMOK) trading at $1.46, up 0.03 (2.10%)

Advanced Cell Technology Inc (OTCBB:ACTC) trading at $ 0.2051, up 0.0053 (2.65%) trading on
over 18 Million shares in volume

GENEREX BIOTECH CORP (OTCBB:GNBT) trading up at $0.30 down 0.00 (0.67%)

Ecosphere Technologies, Inc. (ESPH.OB) trading at $0.64, up 0.08 (15.18%)

OTCBB Stocks to Watch News and Industry Commentary
Advanced Cell Technology Inc (OTCBB:ACTC)

Recent News;

Advanced Cell Technology Cleared to Test Stem-Cell Therapy for Vision Loss

“Advanced Cell Technology Inc. said it was cleared by U.S. regulators to test a therapy made
from embryonic stem cells in patients with macular degeneration, a leading cause of vision loss.

Doctors will inject retinal cells made from stem cells into the eyes of 12 people with the so-called
dry form of macular degeneration, said Gary Rabin, interim chairman and chief executive officer
of the Marlboro, Massachusetts-based company. The disease affects about 15 million Americans
and new therapies may generate as much as $30 billion in sales, Rabin said.”
Full Article:

Advanced Cell Technology Receives FDA Clearance For Clinical Trials Using Embryonic
Stem Cells to Treat Age-Related Macular Degeneration

“Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative
medicine, announced today that the US Food and Drug Administration (FDA) has cleared
the Company’s Investigational New Drug (IND) application to treat Dry Age-Related Macular
Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic
stem cells (hESCs). ACT is now permitted to initiate a Phase I/II multicenter clinical trial to treat
patients with Dry AMD, the most common form of macular degeneration in the world. There are
currently no treatments available for this prevalent disease of an aging global population. Dry
AMD, representing a substantial global market opportunity and afflicts between 10-15 million

Full Article:
About Advanced Cell Technology Inc (OTCBB:ACTC)

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the
field of regenerative medicine. For more information, visit

Recent News:

Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi
Technology in the Development of Therapeutic Vaccines for Cancer
“WORCESTER, Mass., Jan. 6, 2011, Generex Biotechnology Corporation (,

together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc.
(, and RXi Pharmaceuticals Corporation (
(NasdaqCM: RXII), a recognized leader in RNAi-based therapeutics, today announced that they
have obtained positive early research data from their collaboration to explore the use of RXi's
RNAi technology to develop proprietary vaccine formulations for active immunotherapy”
Full Article:

Generex is engaged in the research, development, and commercialization of drug delivery
systems and technologies. Generex has developed a proprietary platform technology for the
delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).
The Company's proprietary liquid formulations allow drugs typically administered by injection
to be absorbed into the body by the lining of the inner mouth using the Company's proprietary
RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in
Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly
owned subsidiary of Generex. The core platform technologies of Antigen Express comprise
immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune
diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in
immunotherapy. One of its platform technologies relies on inhibition of expression of the
Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of
expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and
prevents the further growth of cancer cells. For more information, visit the Generex website at or the Antigen Express website at

Amarok Resources, Inc. (OTCBB: AMOK)

About Amarok Resources, Inc. (OTCBB: AMOK)

Amarok Resources is a US based exploration and development Company, focusing on the
acquisition and development of Gold and Silver projects which demonstrate high probability for
near term production. Amarok is a fully reporting public company quoted on the OTCBB under the
symbol AMOK

Ecosphere Technologies, Inc. (ESPH.OB)
About Ecosphere Technologies, Inc. (ESPH.OB):
“Ecosphere Technologies, Inc. (OTCBB:ESPH - News) is a diversified water engineering
and environmental services company. The Company provides environmental services and
technologies for use in large-scale and sustainable applications across industries, nations and

Get Free Investor Stock alerts on OTC stocks and microcap stocks at Investor

About is a leading global investor and industry research resource portal specialized in sector

investing, covering leading industry sectors including mining and gold stocks, in addition to global markets
including China, India, the Middle East and Australia. is known for its comprehensive
stock directories in each sector and sector specific newswires.

Disclaimer: is a third party publisher of news and research .Our sites do not make
recommendations, but offer information portals to research news, articles, stock lists and recent research.
Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This
site is currently compensated by featured companies, news submissions and online advertising.
None of the clients featured in this are advertising with Disclaimer: Disclosure:

C Van Zant: 800-665-0411 -

Source -